AtoCap's Lead Program for
Recurrent Urinary Tract Infections
CapFuran reformulates nitrofurantoin into a targeted, intravesical therapy delivering antibiotic directly into bladder cells and biofilms where oral antibiotics cannot reach.
A Common Infection Turned Lifelong Struggle
Urinary tract infections affect over 400 million people every year. For millions, what begins as a routine infection becomes a chronic, untreatable condition.
"I was diagnosed with a UTI in 2016. Nine years later, after being treated with 11 different antibiotics, I still have the same infection. I cannot work. I cannot travel. Every single facet of my life I once took for granted has been taken away." Patient living with recurrent UTIs
Behind every prescription are urologists and GPs doing their best, knowing that each new course of antibiotics carries its own cost and declining odds of success.
Existing Treatments Cannot Reach Embedded Infections
Current UTI therapies including antibiotics and vaccines fail to penetrate sufficiently into the bladder wall to kill bacteria embedded inside cells or producing a biofilm.
Symptoms may temporarily subside, but the infection persists. Embedded bacteria survive, later multiply, and produce the same cycle of relapse. The patient appears symptom-free, but the infection is never truly resolved.
Each failed course increases resistance risk and leaves the patient more vulnerable than before.
| Therapy | Limitation | Result |
|---|---|---|
| Oral Antibiotics | Reaches free bacteria only | Relapse |
| IV Treatments | Poor tissue penetration | Resistance |
| Vaccines | Do not eliminate intracellular reservoirs | Inconsistent |
| CapFuran | Reaches biofilms & intracellular reservoirs | >90% Reduction |
% bacterial reduction vs. placebo — human bladder organoid model
CapFuran® substantially improves bacterial killing vs. other treatments. Source: Lau W, Rohn J et al. Journal of Controlled Release, 2020. Human bladder organoid model.
CAPTURE: Phase I/IIa First-in-Human Study
CAPTURE is designed to generate decision-grade safety data and early efficacy signals unlocking early partnering discussions and a clear path into registration-enabling development.
CAPTURE Trial Timeline
Voices From the Patient Community
Recurrent UTIs profoundly affect quality of life. These testimonies reflect the lived experience of patients for whom current treatments have not been enough.
